FIGURE

Fig. 3

ID

ZDB-FIG-240606-28

Publication

Beckmann et al., 2024 - Assessment of a novel NRAS in-frame tandem duplication causing a myelodysplastic/myeloproliferative neoplasm

Other Figures

All Figure Page

Back to All Figure Page

Fig. 3

Targeted treatment in NRASITD-zebrafish embryos. (A) The NRAS-plasmid was coinjected with Tol2 transposase messenger RNA (mRNA) into the single-cell embryo. Zebrafish embryos were incubated with trametinib or PD0325901 from 12 to 48 hours post fertilization (hpf) when analysis of the caudal hematopoietic tissue (CHT) was performed. (B) Images show CHT smears stained with May-Grünwald Giemsa (MGG) stain in fli1a:NRASITDG0mosaic and uninjected Tg(fli1a:Gal4) embryos as well as trametinib- and PD0325901-treated fli1a:NRASITDG0mosaic embryos. Scale bar: 10 µm. (C) Shown are ratios of cell populations in CHT smears from four embryos per condition as percentages. fli1a:NRASITDG0mosaic embryos showed a significant increase in immature myeloid cells (Χ2 [2, n=4] = 32.14, p < 0.001). After treatment of fli1a:NRASITDG0mosaic embryos with PD0325901 as well as with trametinib, the cell fractions in the CHT showed no difference compared with uninjected Tg(fli1a:Gal4) embryos and a significant decrease in immature myeloid cells compared with fli1a:NRASITDG0mosaic embryos (Χ2 [2, n=4] = 49.78, p < 0.001) and (Χ2 [2, n=4] = 74.66, p < 0.001) for trametinib.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Exp. Hematol.